Pharmaceutical intermediates
Trofinetide Intermediates
2 pharmaceutical intermediates for Trofinetide. Indication: Rett Syndrome.
About Trofinetide
- Originator
- Walter Reed Army Institute; Polynovo; Neuren Pharmaceuticals Ltd
- Indication
- Rett Syndrome
- Approved Date
- 03/10/2023
- NCE Patent
- 03/10/2028
- DS/DP
- 01/27/2032
Available intermediates
2 intermediates currently listed for Trofinetide. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (S)-2-Methylproline | 42856-71-3 | / | / |
| 2-Methyl-L-proline Methyl ester hydrochloride | 220060-08-2 | / | / |
Building toward Trofinetide?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →